Indian drugmaker Sun Pharma to buy U.S. firm Organon in $11.75 billion deal

SHANGHAI, CHINA - NOVEMBER 05: People visit the booth of Organon during the 7th China International Import Expo (CIIE) at the National Exhibition and Convention Center (Shanghai) on November 5, 2024 in Shanghai, China. The 7th China International Import Expo (CIIE) kicked off in Shanghai on November 5. (Photo by Tang Yanjun/China News Service/VCG via ) China News Service | China News Service | India's Sun Pharmaceutical Industries will acquire New Jersey-based Organon & Co in an all-cash deal that values the U.S. company at $11.75 billion, including debt. The Indian generic drugmaker will acquire all outstanding shares of Organon for $14 apiece, according to an exchange filing Monday by Sun Pharmaceutical . "Following a comprehensive review of strategic alternatives, our Board determined that this all‑cash transaction offers compelling and immediate value to Organon stockholders," said Carrie Cox, executive chair at Organon, in the joint statement. Organon , which ​was ​spun off from ‌Merck in 2021, specializes in women's health and biosimilars and has more than 70 products that are sold across 140 countries. The acquisition will help lift Sun Pharma, India's largest drugmaker, into the top 25 global pharmaceutical companies, with a revenue of $12.4 billion, according to the press statement. "This transaction is a logical next step in strengthening Sun Pharma's global business," said Kirti Ganorkar, managing director at Sun Pharma. …